Repligen RGEN shares are trading higher on Wednesday after the company reported better-than-expected first-quarter EPS and sales results.
Replige reported quarterly earnings of 32 cents per share, which beat the analyst consensus estimate of 21 cents. The company reported quarterly sales of $76.1 million, which beat the analyst consensus estimate of $71.19 million.
Repligen is a life sciences company. It develops and commercializes innovative bioprocessing technologies and systems that increase efficiencies and flexibility in the process of manufacturing biological drugs. The company's customers include life science companies, global biopharmaceutical companies, and contract manufacturers worldwide.
Repligen shares were trading up 7.88% at $41.59 on Wednesday. The stock has a 52-week range between $125.44 and $65.62.
Related Links:
Gilead's Remdesivir Granted FDA Emergency Use To Treat COVID-19
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
